Siponimod

(Mayzent®)

Siponimod

Drug updated on 4/18/2024

Dosage FormTablet (oral; 0.25 mg, 1 mg, 2 mg)
Drug ClassSphingosine 1-phosphate receptor modulators
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Siponimod (Mayzent) is indicated for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It targets sphingosine-1-phosphate receptors and requires prior testing for CYP2C9 genotype to adjust the dose accordingly.
  • Seven systematic reviews/meta-analyses were analyzed to gather information about the safety and effectiveness of siponimod compared to other drugs used in treating similar conditions.
  • Among Disease Modifying Therapies (DMTs), siponimod was found to be superior in controlling disease progression, alongside mitoxantrone and ocrelizumab. It demonstrated a significant impact on neuroimaging markers, such as changes in total volume of lesions visible through T2-weighted image contrast.
  • Siponimod showed strong efficacy in reducing the annualized relapse rate compared with 19 other DMTs for relapsing forms of MS and was identified as superior to placebo in preventing clinical relapses.
  • The risk profile associated with siponimod varies depending on individual factors and potential genetic predispositions like CYP2C9 genotypes, which may affect tolerability. While detailed data comparing adverse events between siponimod and other drugs were not provided, the varying degrees of risk associated with different DMTs must be considered.
  • Comparisons within the class effect group involving another S1P receptor modulator, Fingolimod, revealed increased cardiovascular risks that necessitate rigorous monitoring during treatment. This highlights the importance of considering patient-specific factors in treatments like siponimod that affect cardiovascular health.